Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at StockNews.com

StockNews.com upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday morning.

A number of other research firms have also weighed in on REGN. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a research report on Thursday, July 11th. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an outperform rating and a $1,150.00 price objective for the company. Royal Bank of Canada reaffirmed an outperform rating and issued a $1,250.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, September 5th. Canaccord Genuity Group reaffirmed a buy rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an overweight rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $1,164.46 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a market cap of $128.31 billion, a PE ratio of 34.40, a price-to-earnings-growth ratio of 3.86 and a beta of 0.12. The stock has a 50-day moving average of $1,121.84 and a 200-day moving average of $1,024.82. Regeneron Pharmaceuticals has a 52-week low of $769.19 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter last year, the company posted $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock valued at $11,498,705 over the last quarter. 7.48% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the company. West Paces Advisors Inc. grew its position in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $26,000. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at about $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.